Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants With COPD

NCT07684820 is registered in ClinicalTrials.gov with Expedition Therapeutics, Inc as lead sponsor.

NCT NCT07684820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07684820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants With COPD
Lead sponsor
Expedition Therapeutics, Inc
Phase
Phase 2
Overall status
Recruiting
Start date
June 30, 2026
Completion date
July 11, 2028
Enrollment
600 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease (copd)